))
A Discussion with Brian Finn of Findell Capital: Biotech Investing, Liquidia & ProQR
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on October 16, 2023 23:24 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337249290 series 3380517
Contenuto fornito da Encode Ideas, L.P., Encode Ideas, and L.P.. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Encode Ideas, L.P., Encode Ideas, and L.P. o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
An interview with Brian Finn of Findell Capital, where we discuss his perspective on small-cap investing. During the interview, we discuss two of Brian's favorite health care names, Liquidia and ProQR, as well as his previous success with MiMedx. To learn more about Findell Capital please visit their website https://findell.us/
Companies discussed during the podcast;
- Liquidia Corporation (Nasdaq: LQDA)
- ProQR Therapeutics N.V. (Nasdaq: PRQR)
- MiMedx Group Inc (Nasdaq: MDXG)
- United Therapeutics Corporation (Nasdaq: UTHR)
- MannKind Corporation (Nasdaq: MNKD)
- Editas Medicine Inc (Nasdaq: EDIT)
7 episodi
Condividi
